Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Observational Study on Treatment Patterns and ctDNA HRR Evaluation in Aggressive High-volume Metastatic Hormone-sensitive Prostate Cancer in Russian Federation

NCT07052578 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07052578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07052578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Observational Study on Treatment Patterns and ctDNA HRR Evaluation in Aggressive High-volume Metastatic Hormone-sensitive Prostate Cancer in Russian Federation
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 30, 2025
Completion date
November 30, 2028
Enrollment
400 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer